Safety and immunogenicity of low and high doses of trivalent live cold- adapted influenza vaccine administered intranasally as drops or spray to healthy children

Journal of Infectious Diseases

Volumn 177, Issue 5, 1998, Pages 1394-1397

  King Jr , James C ^a   Lagos, Rosanna ^b   Bernstein, David I ^b   Piedra, Pedro A ^b   Kotloff, Karen ^b   Bryant, Martin ^b   Cho, Iksung ^b   Belshe, Robert B ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; NOSE SPRAY; TRIPLE VACCINE;

AEROSOL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INTRANASAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VIRUS SHEDDING; VIRUS STRAIN;

EID: 0031925541     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517822     Document Type: Article

References (10)

1. Maassab HF, Kendal AP, Abrams GD, Monto AS. Evaluation of a cold-recombinant influenza virus vaccine in ferrets. J Infect Dis 1982; 146: 780-90.
2. Maassab HF, Shaw MW, Heilman CA. Live influenza virus vaccine. In: Plotkin SA, Mortimer EA, eds. Vaccines. 2nd ed. Philadelphia: WB Saunders, 1994:781-801.
3. Wright PF, Okabe N, McKee KT, Maasab HF, Karzon DT. Cold-adapted recombinant influenza A virus vaccines in seronegative children. J Infect Dis 1982:146:71-9.
4. Cox NJ, Maasab HF, Kendal AP. Comparative studies of wild-type and cold-mutant (temperature sensitive) influenza viruses: nonrandom re-assortment of genes during preparation of live virus vaccine candidates by recombination at 25° between recent H3N2 and H1N1 epidemic strains and cold-adapted A/Ann Arbor/6/60. Virology 1979;97:190-4.
5. Swierkosz EM, Newman FK, Anderson EL, et al. Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children. J Infect Dis 1994;169:1121-4.
6. Gruber WC, Belshe RB, King JC, et al. Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. J Infect Dis 1996; 173:1313-9.
7. Piedra PA, Glezen WP, Mbawuike I, et al. Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young children. Vaccine 1993; 11:718-24.
8. Romanova JR, Ermachenko TA, Alexandrova Gl, et al. Interference between cold-adapted (ca) influenza A and B vaccine reassortants or between ca reassortants and wild-type strains in eggs and mice. Vaccine 1994; 12:23-7.
9. Robertson HE, Acker MS, Dillenberg HO, et al. Community-wide use of a balanced trivalent oral poliovirus vaccine (Sabin). Can J Public Health 1962;53:179-91.
10. Gruber WC, Hinson HP, Holland KL, Thompson JM, Reed G, Wright PF. Comparative trial of large-particle aerosol and nose drops administration of live attenuated influenza vaccines. J Infect Dis 1993; 168:1282-5.